

Iterative Cytoreductive Surgery Associated With Hyperthermic Intraperitoneal Chemotherapy for Treatment of Peritoneal Carcinomatosis of Colorectal Origin With or Without Liver Metastases

Reza Kianmanesh, MD, PhD,* Stefano Scaringi, MD,* Jean-Marc Sabate, MD, PhD,† Benjamin Castel, MD,* Nathalie Pons-Kerjean, MD, PhD,‡ Benoit Coffin, MD, PhD,† Jean-Marie Hay, MD,* Yves Flamant, MD,* and Simon Msika, MD, PhD*




FIGURE 2. Overall actuarial survival (Kaplan–Meier). Median survival: 38.4 months (CI, 32.8–43.9 months). Two-year survival: 72%, 4-year survival: 44%. CS, cytoreductive surgery; HIPEC, hyperthermic intraperitoneal chemotherapy.




FIGURE 3. Survival according to the extent of the initial disease ($P = 0.009$). Malignant nodules less than 5 mm in diameter localized in one part of the abdomen (Gilly 1), and diffuse nodules in the whole abdomen (Gilly 2) (gray line, median survival not reached). Localized or diffuse malignant nodules between 5 and 20 mm in diameter (Gilly 3) and large malignant nodules more than 20 mm in diameter (Gilly 4) (plain line, median survival: 33.8 months). CS, cytoreductive surgery; HIPEC, hyperthermic intraperitoneal chemotherapy.





FIGURE 4. Survival according to the completeness of cancer resection ($P < 0.0001$). CCR-0, no macroscopic disease (black interrupted line; median survival not reached); CCR-1, residual disease less than 5 mm in diameter (gray interrupted line, median survival: 63 months). CCR-2: residual disease more than 5 mm in diameter (solid line; median survival: 14.6 months). CS, cytoreductive surgery; HIPEC, hyperthermic intraperitoneal chemotherapy.

A Simple Tumor Load-Based Nomogram for Surgery in Patients with Colorectal Liver and Peritoneal Metastases

Dominique Elias, ¹
Charles Honoré, ²

Eric Dumont, MD¹,
Alexandre Cote, MD, PhD²



At risk

119	107	77	43	29	23	12	HIPEC
37	29	19	11	6	5	3	HIPEC+ LR
287	239	177	113	77	57	43	LR

FIG. 1 Overall survival according to patient group. *HIPEC* hyperthermic intraperitoneal chemotherapy, *LR* liver resection

ANNALS OF

2014

SURGICAL ONCOLOGY

OFFICIAL JOURNAL OF THE SOCIETY OF SURGICAL ONCOLOGY




FIG. 2 Nomogram predicting 1-, 3-, and 5-year survival. *LM* liver metastasis, *PCI* peritoneal carcinomatosis index, *LR* liver resection, *HIPEC* hyperthermic intraperitoneal chemotherapy. For example a patient with 5 liver metastases and a *PCI* of 10 will score (on the upper ruler): 7.5 points for the metastasis, 25 points for the *PCI*, and

2.5 points for the planned procedure resulting in 35 total points. On the lower ruler, the 35 total points predict a 1-year survival rate just below 90 %, 3-year survival rate of between 40 and 50 %, and a 5-year survival rate between 20 and 30 %




FIG. 2 Nomogram predicting 1-, 3-, and 5-year survival. *LM* liver metastasis, *PCI* peritoneal carcinomatosis index, *LR* liver resection, *HIPEC* hyperthermic intraperitoneal chemotherapy. For example a patient with 5 liver metastases and a PCI of 10 will score (on the upper ruler): 7.5 points for the metastasis, 25 points for the PCI, and

2.5 points for the planned procedure resulting in 35 total points. On the lower ruler, the 35 total points predict a 1-year survival rate just below 90 %, 3-year survival rate of between 40 and 50 %, and a 5-year survival rate between 20 and 30 %

Nomogram for Metastatic Colorectal Patients




FIG. 2 Nomogram predicting 1-, 3-, and 5-year survival. *LM* liver metastasis, *PCI* peritoneal carcinomatosis index, *LR* liver resection, *HIPEC* hyperthermic intraperitoneal chemotherapy. For example a patient with 5 liver metastases and a *PCI* of 10 will score (on the upper ruler): 7.5 points for the metastasis, 25 points for the *PCI*, and

2.5 points for the planned procedure resulting in 35 total points. On the lower ruler, the 35 total points predict a 1-year survival rate just below 90%, 3-year survival rate of between 40 and 50%, and a 5-year survival rate between 20 and 30%.

Extrahepatic disease Peritoneal

Cumulative Survival 2005-2014 (n=355)

